-
Sling Therapeutics Presents Data from Phase 2b/3 LIDS Clinical Trial Demonstrating Durability of Linsitinib in Thyroid Eye Disease at ASOPRS 57th Annual Fall Scientific Symposium
Linsitinib achieved a statistically significant proptosis responder rate of 52% vs. 19% for placebo at Week 24 (p=0.010) 82% of Week 24 proptosis responders maintained their response through Week 72 (48 weeks after treatment completion), representing a highly favorable durability profile Low incidence of IGF-1R–associated adverse events of special interest; no treatment-related hearing impairment…
-
Sling Therapeutics to Present Data from Phase 2b/3 LIDS Trial of Oral IGF-1R Inhibitor Linsitinib in Thyroid Eye Disease at ASOPRS 57th Annual Fall Scientific Symposium
ANN ARBOR, MI, October 5, 2026 – Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced that data from its Phase 2b/3 LIDS trial of linsitinib in adults with moderate to severe active TED will be presented at the American Society…
-
Sling Therapeutics Announces First Patients Dosed in Global Phase 3 ORBIT Pivotal Trial of Linsitinib for Thyroid Eye Disease
Linsitinib is the first and only oral IGF-1R inhibitor in Phase 3 development, poised to address multiple TED patient populations Actively enrolling patients ANN ARBOR, MI, September 16, 2026 – Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the first…
-
Sling Therapeutics Announces $123 Million Series C Financing to Advance Phase 3 Development of its Oral Small Molecule IGF-1R Inhibitor for Thyroid Eye Disease
Commenced global Phase 3 ORBIT pivotal trial evaluating linsitinib in adults with moderate to severe active thyroid eye disease (TED) Linsitinib is the first and only oral small molecule therapy to significantly reduce proptosis in TED, with more convenient dosing compared to currently available IV and injectable IGF-1R inhibitors U.S. Fast Track Designation granted to…
-
Sling Therapeutics Appoints Ken Lock as Chief Commercial Officer
Lock brings over 20 years of commercial leadership experience as Sling prepares for confirmatory Phase 3 study of linsitinib ANN ARBOR, MI, Jun 18, 2025–(BUSINESS WIRE)–Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced the appointment of Ken Lock as Chief…
-
Sling Therapeutics Announces Positive Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with Thyroid Eye Disease
Ann Arbor, MI, January 14, 2025 /PR NEWSWIRE/ – Sling Therapeutics, Inc., a late-stage biopharmaceutical company focused on the development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced topline efficacy and safety data from the Phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe…
-
Sling Therapeutics to Announce Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with Thyroid Eye Disease at the 43rd Annual J.P. Morgan Healthcare Conference
ANN ARBOR, Mich., Jan. 13, 2025 /PRNewswire/ — Sling Therapeutics, Inc., a late-stage biopharmaceutical company focused on the development of an oral small molecule for the treatment of thyroid eye disease (TED), will announce topline data from the Phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe TED at the 43rd Annual J.P. Morgan Healthcare…
-
Sling Therapeutics Appoints Andrew Guggenhime to its Board of Directors
ANN ARBOR, Mich., Jan. 7, 2025 /PRNewswire/ — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced the appointment of Andrew Guggenhime, an experienced biopharma executive, to its Board of Directors. “Andrew is a distinguished and highly respected leader…
-
Sling Therapeutics Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
ANN ARBOR, Mich., Jan. 6, 2025 /PRNewswire/ — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced that Raymond Douglas, M.D., Ph.D., Chief Scientific Officer of Sling, will present at the 43rd Annual J.P. Morgan Healthcare Conference being held…
-
Sling Therapeutics to Participate in Upcoming Investor Conferences
Ann Arbor, MI, November 8, 2023 — Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), will be participating in three upcoming investor conferences in November 2023. Details of the presentations can be found below. Stifel 2023 Healthcare Conference Chief Executive…
